Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | AKT1S1 | Q96B36 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471054 | 0.84 | RPS6KB1 (0.51) | ACHEAKT1S1TSHRRPS6KB1 | |
| SCHEMBL15797503 | 0.83 | DPP4 (0.53) | DPP4KDM4ESLC6A2P2RX7MAPT | |
| SCHEMBL8276868 | 0.83 | DPP4 (0.60) | DPP4P2RX7MAPTAKT1S1RPS6KB1 | |
| SCHEMBL15797636 | 0.83 | DPP4 (0.49) | ACHEDPP4KDM4ESLC6A2P2RX7 | |
| SCHEMBL18824466 | 0.83 | DPP4 (0.60) | DPP4P2RX7MAPTAKT1S1RPS6KB1 | |
| SCHEMBL12295763 | 0.83 | ACHE (0.53) | ACHEKDM4ESLC6A2P2RX7MAPT | |
| SCHEMBL856294 | 0.83 | DPP4 (0.64) | DPP4SLC6A2TSHRRPS6KB1ALDH1A1 | |
| SCHEMBL20746267 | 0.83 | DPP4 (0.64) | DPP4SLC6A2TSHRRPS6KB1ALDH1A1 | |
| SCHEMBL15797523 | 0.83 | SLC6A2 (0.67) | ACHEDPP4KDM4ESLC6A2P2RX7 | |
| SCHEMBL5104299 | 0.83 | DPP4 (0.52) | DPP4SLC6A2P2RX7MAPTRPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718774-B2 | Indole carboxamide derivatives as P2X7 receptor antagonist | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-01 | — | — | US | claimed |
| EP-2931717-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | claimed |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-12 | — | — | US | claimed |
| EP-2931717-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-10-21 | — | — | EP | claimed |
| EP-2547656-B1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2015-09-30 | — | — | EP | claimed |
| EP-2845593-A1 | Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease | Novartis AG (CH) | 2015-03-11 | — | — | EP | claimed |
| WO-2014091415-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-19 | — | — | WO | claimed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2024-02-22 | — | — | US | disclosed |
| CN-113891744-A | Pyridine and pyrazine derivatives for the treatment of CF, COPD and bronchiectasis | 诺华股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| WO-2020250116-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | NOVARTIS AG (CH) | 2020-12-17 | — | — | WO | disclosed |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2020-12-10 | — | — | US | disclosed |
| EP-2547656-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG | 2012-11-01 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110086847-A1 | THIADIAZOLE MODULATORS OF BETA ADRENERGIC RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| EP-2044031-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | Bayer HealthCare AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006479-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | ACHE 1644/4885DPP4 3353/4885KDM4E 1779/4885 |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | ACHE 1390/4885DPP4 3363/4885KDM4E 2343/4885 |
| US-20110086847-A1 | THIADIAZOLE MODULATORS OF BETA ADRENERGIC RECEPTOR | ADRB3, ADRB2, ADRB1 | ACHE 686/4885DPP4 1878/4885KDM4E 4257/4885 |
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | F2, TFPI, PLAT | ACHE 1054/4885DPP4 170/4885KDM4E 1962/4885 |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | P2RX3, P2RX7, P2RX1 | ACHE 1018/4885DPP4 1374/4885KDM4E 2299/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | ACHE 1523/4885DPP4 3232/4885KDM4E 1465/4885 |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | ACHE 1390/4885DPP4 3363/4885KDM4E 2343/4885 |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | ACHE 1644/4885DPP4 3353/4885KDM4E 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.